According to The Cancer Genome Atlas data on endometrioid endometrial carcinoma, approximately 8% of cases may have POLE mutations, partially including concurrent p53 mutation, and show a favorable prognosis [22]. The gene discussed is TP53; the disease is endometrial endometrioid carcinoma.